CVSI实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 03:58):

Stats
今日成交量	241 919
平均成交量	276 861
市值	7.18M
EPS	$0 ( 2024-03-27 )
下一个收益日期	( $0 ) 2024-06-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.20
ATR14	$0.00200 (4.55%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-15	Dowling Joseph D	Buy	2 500 000	Employee Stock Option (right to buy)
2023-03-15	Grasser Joerg	Buy	1 250 000	Employee Stock Option (right to buy)
2022-10-21	Mccorkle William	Buy	500 000	Employee Stock Option (right to buy)
2022-10-21	Mccorkle William	Buy	0
2022-10-21	Mccorkle William	Buy	0

INSIDER POWER
100.00
Last 97 transactions
Buy: 17 580 526 \| Sell: 13 733 278

音量相关性

長: 0.02 (neutral)

短: 0.25 (neutral)

Signal:(54.779) Neutral

CV Sciences, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CV Sciences, Inc. 相关性 - 货币/商品

0.57
( weak )

0.00
( neutral )

-0.42
( neutral )

CV Sciences, Inc. 财务报表

Annual	2023
营收:	$16.00M
毛利润:	$7.09M (44.27 %)
EPS:	$0.0201

FY	2023
营收:	$16.00M
毛利润:	$7.09M (44.27 %)
EPS:	$0.0201

FY	2022
营收:	$16.21M
毛利润:	$5.55M (34.25 %)
EPS:	$-0.0595

FY	2021
营收:	$20.05M
毛利润:	$8.62M (42.98 %)
EPS:	$-0.140

Financial Reports:

No articles found.

CV Sciences, Inc.

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.